Cancer researchers say patients are living longer thanks to better detection and treatments, but they fear rising case numbers and gaps in data could undermine gains.
Having previously updated the risks specified on the product monograph for one type of Janus Kinase inhibitor, Health Canada now says it can't rule out similar risks for other types.